GPT Healthcare Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

July 8, 2026
Posted by: Kunal Singla
Category: News

GPT Healthcare CMP Rs.157. Market cap Rs.1,281 Cr. PE Not meaningful. 12-month target Rs.158-178.

GPT Healthcare Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with GPT Healthcare shares trading at Rs.157 against a market capitalisation of Rs.1,281 Cr and a price-to-earnings multiple of Not meaningful. As a healthcare services name on the NSE and BSE, GPT Healthcare enters the GPT Healthcare Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

Quarterly financials for GPT Healthcare are not yet fully available on Univest’s data partners for this cycle; investors should track Screener.in and the NSE/BSE filings directly for the GPT Healthcare Q1 Results FY27 result date and cross-check any figures before making investment decisions.

Get Free Investment Predictions and GPT Healthcare Research at Univest

GPT Healthcare (NSE: GPTHEALTH) operates in the healthcare services space and is tracked on Univest under its NSE and BSE listings ahead of the GPT Healthcare Q1 Results FY27 season, forming the base against which the GPT Healthcare Q1 Results FY27 estimates in this article are built. This GPT Healthcare Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Table of Contents

GPT Healthcare Q1 FY27 Estimates

Metric	Detail
CMP	Rs.157
Market Cap	Rs.1,281 Cr
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.158-178

Univest, a SEBI-Registered Investment Advisor, Tracks GPT Healthcare Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. Occupancy and ARPOB Trends

Occupancy and ARPOB improvement across hospital and diagnostic networks is one of the primary variables that analysts are tracking ahead of GPT Healthcare’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the GPT Healthcare share price target or faces renewed pressure.

2. Capacity Addition

Capacity addition through new beds or centres supporting medium-term growth is one of the primary variables that analysts are tracking ahead of GPT Healthcare’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the GPT Healthcare share price target or faces renewed pressure.

3. Case Mix Improvement

Case mix improvement toward higher-margin specialties aiding profitability is one of the primary variables that analysts are tracking ahead of GPT Healthcare’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the GPT Healthcare share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track GPT Healthcare’s live price and Q1 FY27 result updates.

Key Risks to the GPT Healthcare Q1 Results FY27 Outlook

Slower occupancy ramp-up in newly added capacity affecting near-term margins.
Regulatory changes to pricing or insurance reimbursement norms.
Talent cost inflation for specialist doctors and clinical staff.

Recent Performance Context

Detailed recent-quarter financials for GPT Healthcare were not available from Univest’s data partners at the time of writing. Investors should check Screener.in or the company’s exchange filings for the latest verified numbers before the Q1 FY27 results.

Technical Analysis Ahead of GPT Healthcare Q1 Results FY27

GPT Healthcare shares last traded at Rs.157. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the GPT Healthcare Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the GPT Healthcare Q1 Results FY27 trailing-growth framework points to a range of Rs.154-166 for GPT Healthcare, contingent on the GPT Healthcare Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this GPT Healthcare Q1 Results FY27 view for GPT Healthcare works out to Rs.158-178, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into GPT Healthcare Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this GPT Healthcare Q1 Results FY27 analysis would put GPT Healthcare in a Rs.167-195 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the GPT Healthcare Q1 Results FY27 Print

Revenue and PAT versus the GPT Healthcare Q1 Results FY27 estimate range in this preview.
Management commentary on FY27 growth guidance and margin trajectory relevant to the GPT Healthcare Q1 Results FY27 narrative.
Occupancy and ARPOB improvement across hospital and diagnostic networks
Slower occupancy ramp-up in newly added capacity affecting near-term margins

Conclusion on GPT Healthcare Q1 Results FY27

GPT Healthcare enters the Q1 FY27 results season trading at Rs.157, with the 12-month Uniresearch target range of Rs.158-178 reflecting a tracking stance. Investors tracking the GPT Healthcare Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on GPT Healthcare Q1 Results FY27

When are GPT Healthcare Q1 FY27 results expected?

Ans. GPT Healthcare’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the GPT Healthcare Q1 FY27 revenue estimate?

Ans. Detailed quarterly estimates are not available for GPT Healthcare at this time; check Screener.in or the company’s exchange filings for verified numbers.

What is the GPT Healthcare share price target?

Ans. The 12-month Uniresearch estimate for GPT Healthcare share price target is Rs.158-178, based on trailing growth and current valuation multiples.

Is GPT Healthcare a good buy before Q1 FY27 results?

Ans. GPT Healthcare is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in GPT Healthcare’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and occupancy and ARPOB improvement across hospital and diagnostic networks.

Where can I track GPT Healthcare share price live?

Ans. GPT Healthcare share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.